{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"172","value":"1.36"},{"groupId":"OG001","spread":"59","value":"1.33"},{"groupId":"OG002","spread":"61","value":"3.33"},{"groupId":"OG003","spread":"93","value":"7.32"},{"groupId":"OG004","spread":"75","value":"25.4"},{"groupId":"OG005","spread":"26","value":"33.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"Serum concentration of Pegilodecakin is reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who received 0.08 or 0.1 mg of Pegilodecakin once QD administered SC across all parts are grouped under this arm.","id":"OG000","title":"Pegilodecakin 0.08/0.1 mg"},{"description":"Participants who received 0.2 or 0.25 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.","id":"OG001","title":"Pegilodecakin 0.2/0.25 mg"},{"description":"Participants who received 0.4 or 0.5 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.","id":"OG002","title":"Pegilodecakin 0.4/0.5 mg"},{"description":"Participants who received 0.8 or 1 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.","id":"OG003","title":"Pegilodecakin 0.8/1 mg"},{"description":"Participants who received 1.6 or 2 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.","id":"OG004","title":"Pegilodecakin 1.6/2 mg"},{"description":"Participants who received 3.2 or 4 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.","id":"OG005","title":"Pegilodecakin 3.2/4 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who received at least one dose of the study intervention and had evaluable PK data. Per protocol, PK data was pre-specified to be analyzed by Pegilodecakin dose levels across all parts.","reportingStatus":"POSTED","timeFrame":"Day 29","title":"Pharmacokinetic (PK): Serum Concentration of Pegilodecakin","type":"PRIMARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}